Several Lario Therapeutics Ltd. patents describe new voltage-dependent R-type calcium channel subunit α-1E (Cav2.3) antagonists reported to be useful for the treatment of neurodegeneration, epilepsy, Parkinson’s disease, cerebral vasospasm, pain, CDKL5 deficiency, endocrine and neurodevelopmental disorders, among others.